NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
02 April 2025
| Name: | MEMPHASYS LIMITED (MEM) | |||||||||
| ISIN: | AU000000MEM5 | |||||||||
| Date of Listing: | 14 May 2007 | |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 120 047 556ABN: 33 120 047 556
Registration Date: 11 July 2006
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| MEMPHASYS LIMITED | 06/07/2016 | |
| NUSEP HOLDINGS LTD | 04/11/2010 | 06/07/2016 |
| NUSEP LTD | 04/11/2010 |
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising. | 12/09/2024 |
The company plans to raise A$1.0 million through a placement, supported by existing shareholders and new investors. Memphasys will offer shareholders access to the same terms via a Share Purchase Plan. Eligible shareholders can raise up to A$1.0 million. Proceeds will be used for the finalization of the FelixTM clinical trial, an equine fertility study, and a study on oxidative stress. | 12/09/2024 |
The securities of Memphasys Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a capital raising. | 11/09/2024 |
The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising. | 17/08/2022 |
Placement to raise approximately $1.6M at 2 cents per share. Fully underwritten, non-renounceable entitlement offer to raise up to $1.76M (1 new share for every 9 held on the record date at 2 cents per share). Funds will be used predominantly to continue commercialisation of the Felix System, undertake Felix System clinical trials and other regulatory activities, and to continue the development of other pipeline products with the University of Newcastle research team. | 17/08/2022 |
On 10 August 2022, the Supreme Court of Western Australia heard the company's application seeking orders in relation to four inadvertent administrative errors whereby the Company failed to lodge a cleansing notice. The Court has granted orders validating any subsequent offer for sale or sale of the Uncleansed Shares. The company is now able to shift itsfocusto completion of its proposed capital raising, which shall comprise a placement and pro-rata entitlement offer. The comapny will remain in voluntary suspension to facilitate an orderly market in its securities pending release of an announcement with respect to the capital raising, which is anticipated to be on or around Monday, 15 August 2022. | 11/08/2022 |
The company releases a cleansing statement in relation to the issue of 1,333,334 Shares, which was completed on 21 October 2019. | 02/08/2022 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 29/07/2022 |
The securities of Memphasys Limited ("˜MEM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a court application concerning the failure to lodge cleansing notices in connection with the issue of shares on 3 September 2015, 30 May 2017, 21 October 2019 and 17 July 2020. | 29/07/2022 |
we understand that on or about this date the company consolidated its shares 1 for 15 | 17/08/2018 |
name changed from Nusep Holdings Ltd | 06/07/2016 |
The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising. | 12/09/2024 |
The company plans to raise A$1.0 million through a placement, supported by existing shareholders and new investors. Memphasys will offer shareholders access to the same terms via a Share Purchase Plan. Eligible shareholders can raise up to A$1.0 million. Proceeds will be used for the finalization of the FelixTM clinical trial, an equine fertility study, and a study on oxidative stress. | 12/09/2024 |
The securities of Memphasys Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a capital raising. | 11/09/2024 |
The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising. | 17/08/2022 |
Placement to raise approximately $1.6M at 2 cents per share. Fully underwritten, non-renounceable entitlement offer to raise up to $1.76M (1 new share for every 9 held on the record date at 2 cents per share). Funds will be used predominantly to continue commercialisation of the Felix System, undertake Felix System clinical trials and other regulatory activities, and to continue the development of other pipeline products with the University of Newcastle research team. | 17/08/2022 |
On 10 August 2022, the Supreme Court of Western Australia heard the company's application seeking orders in relation to four inadvertent administrative errors whereby the Company failed to lodge a cleansing notice. The Court has granted orders validating any subsequent offer for sale or sale of the Uncleansed Shares. The company is now able to shift itsfocusto completion of its proposed capital raising, which shall comprise a placement and pro-rata entitlement offer. The comapny will remain in voluntary suspension to facilitate an orderly market in its securities pending release of an announcement with respect to the capital raising, which is anticipated to be on or around Monday, 15 August 2022. | 11/08/2022 |
The company releases a cleansing statement in relation to the issue of 1,333,334 Shares, which was completed on 21 October 2019. | 02/08/2022 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 29/07/2022 |
The securities of Memphasys Limited ("˜MEM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a court application concerning the failure to lodge cleansing notices in connection with the issue of shares on 3 September 2015, 30 May 2017, 21 October 2019 and 17 July 2020. | 29/07/2022 |
we understand that on or about this date the company consolidated its shares 1 for 15 | 17/08/2018 |
name changed from Nusep Holdings Ltd | 06/07/2016 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 30/12/2022 | Alison Coutts | 392,500 | $0.014 | $5,417 |
| 30/12/2022 | Andrew Goodall | 1,400,000 | $0.014 | $18,900 |
| 30/12/2022 | Alison Coutts | 392,500 | $0.014 | $5,417 |
| 29/03/2019 | Andrew Goodall | 496,843 | $0.020 | $9,937 |
| 27/09/2018 | Marjan Mikel | 1,000,000 | $0.012 | $12,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Lindley Edwards | Non Exec Chairman | 23/11/2024 |
| Michael Atkins | Independent Director | 14/03/2024 |
| Paul Wright | Independent Director | 13/03/2020 |
| David Ali | Executive Director, CEO | 30/11/2023 |
| Andrew Metcalfe | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Robert Cooke | Non Exec Chairman | 26/04/2022 | 23/11/2024 |
| Alison Coutts | Managing Director, CEO | 29/11/2013 | 01/12/2023 |
| Andrew Goodall | Non Exec Director | 14/03/2012 | 01/12/2023 |
| Shane Hartwig | Non Exec Director | 31/07/2019 | 25/04/2022 |
| Marjan Mikel | Independent Director | 07/06/2018 | 13/03/2020 |
| John Pereira | Independent Director | 30/08/2016 | 07/06/2018 |
| Robert Gilmour | Non Exec Director | 12/04/2016 | 29/09/2016 |
| Mark Gell | Independent Director | 17/10/2014 | 12/04/2016 |
| Michael Graham | Non Exec Director | 10/09/2014 | 04/01/2016 |
| Stephen van der Mye | Non Exec Director | 02/12/2013 | 28/04/2014 |
| Prakash Patel | Director, CEO | 01/12/2012 | 10/02/2014 |
| John Manusu | Non Exec Chairman | 11/09/2006 | 29/11/2013 |
| Hari Nair | Deputy Chairman, Non Exec Director, Managing Director | 11/09/2006 | 29/11/2013 |
| Clifford Eu | Non Exec Director | 01/12/2012 | 29/11/2013 |
| Ward Wescott | Director | 10/10/2011 | 30/11/2012 |
| David Roffe | Director | 10/10/2011 | 30/11/2012 |
| Iain Sorrell | Director | 11/09/2006 | 30/11/2012 |
| William Spee | Director | 01/07/2009 | 19/03/2012 |
| John O'Connor | Director | 10/10/2011 | 19/02/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
